PARP1 is required for chromosomal translocations.

Justin Wray, Elizabeth A. Williamson, Sudha B. Singh, Yuehan Wu, Christopher R. Cogle, David M. Weinstock, Y. Zhang, Suk-Hee Lee, Daohong Zhou, Lijian Shao, Martin Hauer-Jensen, Rupak Pathak, Virginia Klimek, Jac A. Nickoloff, Robert Hromas

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Chromosomal translocations are common contributors to malignancy, yet little is known about the precise molecular mechanisms by which they are generated. Sequencing translocation junctions in acute leukemias revealed that the translocations were likely mediated by a DNA double-strand break repair pathway termed nonhomologous end-joining (NHEJ). There are major 2 types of NHEJ: (1) the classical pathway initiated by the Ku complex, and (2) the alternative pathway initiated by poly ADP-ribose polymerase 1 (PARP1). Recent reports suggest that classical NHEJ repair components repress translocations, whereas alternative NHEJ components were required for translocations. The rate-limiting step for initiation of alternative NHEJ is the displacement of the Ku complex by PARP1. Therefore, we asked whether PARP1 inhibition could prevent chromosomal translocations in 3 translocation reporter systems. We found that 2 PARP1 inhibitors or repression of PARP1 protein expression strongly repressed chromosomal translocations, implying that PARP1 is essential for this process. Finally, PARP1 inhibition also reduced both ionizing radiation-generated and VP16-generated translocations in 2 cell lines. These data define PARP1 as a critical mediator of chromosomal translocations and raise the possibility that oncogenic translocations occurring after high-dose chemotherapy or radiation could be prevented by treatment with a clinically available PARP1 inhibitor.

Original languageEnglish (US)
Pages (from-to)4359-4365
Number of pages7
JournalBlood
Volume121
Issue number21
DOIs
StatePublished - May 23 2013

Fingerprint

Genetic Translocation
Poly(ADP-ribose) Polymerases
Joining
Repair
Poly (ADP-Ribose) Polymerase-1
Chemotherapy
Double-Stranded DNA Breaks
Ionizing radiation
Ionizing Radiation
Dosimetry
Leukemia
Cells
Radiation
Drug Therapy
Cell Line
DNA

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Wray, J., Williamson, E. A., Singh, S. B., Wu, Y., Cogle, C. R., Weinstock, D. M., ... Hromas, R. (2013). PARP1 is required for chromosomal translocations. Blood, 121(21), 4359-4365. https://doi.org/10.1182/blood-2012-10-460527

PARP1 is required for chromosomal translocations. / Wray, Justin; Williamson, Elizabeth A.; Singh, Sudha B.; Wu, Yuehan; Cogle, Christopher R.; Weinstock, David M.; Zhang, Y.; Lee, Suk-Hee; Zhou, Daohong; Shao, Lijian; Hauer-Jensen, Martin; Pathak, Rupak; Klimek, Virginia; Nickoloff, Jac A.; Hromas, Robert.

In: Blood, Vol. 121, No. 21, 23.05.2013, p. 4359-4365.

Research output: Contribution to journalArticle

Wray, J, Williamson, EA, Singh, SB, Wu, Y, Cogle, CR, Weinstock, DM, Zhang, Y, Lee, S-H, Zhou, D, Shao, L, Hauer-Jensen, M, Pathak, R, Klimek, V, Nickoloff, JA & Hromas, R 2013, 'PARP1 is required for chromosomal translocations.', Blood, vol. 121, no. 21, pp. 4359-4365. https://doi.org/10.1182/blood-2012-10-460527
Wray J, Williamson EA, Singh SB, Wu Y, Cogle CR, Weinstock DM et al. PARP1 is required for chromosomal translocations. Blood. 2013 May 23;121(21):4359-4365. https://doi.org/10.1182/blood-2012-10-460527
Wray, Justin ; Williamson, Elizabeth A. ; Singh, Sudha B. ; Wu, Yuehan ; Cogle, Christopher R. ; Weinstock, David M. ; Zhang, Y. ; Lee, Suk-Hee ; Zhou, Daohong ; Shao, Lijian ; Hauer-Jensen, Martin ; Pathak, Rupak ; Klimek, Virginia ; Nickoloff, Jac A. ; Hromas, Robert. / PARP1 is required for chromosomal translocations. In: Blood. 2013 ; Vol. 121, No. 21. pp. 4359-4365.
@article{22957a4e13e54ed2b2447af07e0791ee,
title = "PARP1 is required for chromosomal translocations.",
abstract = "Chromosomal translocations are common contributors to malignancy, yet little is known about the precise molecular mechanisms by which they are generated. Sequencing translocation junctions in acute leukemias revealed that the translocations were likely mediated by a DNA double-strand break repair pathway termed nonhomologous end-joining (NHEJ). There are major 2 types of NHEJ: (1) the classical pathway initiated by the Ku complex, and (2) the alternative pathway initiated by poly ADP-ribose polymerase 1 (PARP1). Recent reports suggest that classical NHEJ repair components repress translocations, whereas alternative NHEJ components were required for translocations. The rate-limiting step for initiation of alternative NHEJ is the displacement of the Ku complex by PARP1. Therefore, we asked whether PARP1 inhibition could prevent chromosomal translocations in 3 translocation reporter systems. We found that 2 PARP1 inhibitors or repression of PARP1 protein expression strongly repressed chromosomal translocations, implying that PARP1 is essential for this process. Finally, PARP1 inhibition also reduced both ionizing radiation-generated and VP16-generated translocations in 2 cell lines. These data define PARP1 as a critical mediator of chromosomal translocations and raise the possibility that oncogenic translocations occurring after high-dose chemotherapy or radiation could be prevented by treatment with a clinically available PARP1 inhibitor.",
author = "Justin Wray and Williamson, {Elizabeth A.} and Singh, {Sudha B.} and Yuehan Wu and Cogle, {Christopher R.} and Weinstock, {David M.} and Y. Zhang and Suk-Hee Lee and Daohong Zhou and Lijian Shao and Martin Hauer-Jensen and Rupak Pathak and Virginia Klimek and Nickoloff, {Jac A.} and Robert Hromas",
year = "2013",
month = "5",
day = "23",
doi = "10.1182/blood-2012-10-460527",
language = "English (US)",
volume = "121",
pages = "4359--4365",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "21",

}

TY - JOUR

T1 - PARP1 is required for chromosomal translocations.

AU - Wray, Justin

AU - Williamson, Elizabeth A.

AU - Singh, Sudha B.

AU - Wu, Yuehan

AU - Cogle, Christopher R.

AU - Weinstock, David M.

AU - Zhang, Y.

AU - Lee, Suk-Hee

AU - Zhou, Daohong

AU - Shao, Lijian

AU - Hauer-Jensen, Martin

AU - Pathak, Rupak

AU - Klimek, Virginia

AU - Nickoloff, Jac A.

AU - Hromas, Robert

PY - 2013/5/23

Y1 - 2013/5/23

N2 - Chromosomal translocations are common contributors to malignancy, yet little is known about the precise molecular mechanisms by which they are generated. Sequencing translocation junctions in acute leukemias revealed that the translocations were likely mediated by a DNA double-strand break repair pathway termed nonhomologous end-joining (NHEJ). There are major 2 types of NHEJ: (1) the classical pathway initiated by the Ku complex, and (2) the alternative pathway initiated by poly ADP-ribose polymerase 1 (PARP1). Recent reports suggest that classical NHEJ repair components repress translocations, whereas alternative NHEJ components were required for translocations. The rate-limiting step for initiation of alternative NHEJ is the displacement of the Ku complex by PARP1. Therefore, we asked whether PARP1 inhibition could prevent chromosomal translocations in 3 translocation reporter systems. We found that 2 PARP1 inhibitors or repression of PARP1 protein expression strongly repressed chromosomal translocations, implying that PARP1 is essential for this process. Finally, PARP1 inhibition also reduced both ionizing radiation-generated and VP16-generated translocations in 2 cell lines. These data define PARP1 as a critical mediator of chromosomal translocations and raise the possibility that oncogenic translocations occurring after high-dose chemotherapy or radiation could be prevented by treatment with a clinically available PARP1 inhibitor.

AB - Chromosomal translocations are common contributors to malignancy, yet little is known about the precise molecular mechanisms by which they are generated. Sequencing translocation junctions in acute leukemias revealed that the translocations were likely mediated by a DNA double-strand break repair pathway termed nonhomologous end-joining (NHEJ). There are major 2 types of NHEJ: (1) the classical pathway initiated by the Ku complex, and (2) the alternative pathway initiated by poly ADP-ribose polymerase 1 (PARP1). Recent reports suggest that classical NHEJ repair components repress translocations, whereas alternative NHEJ components were required for translocations. The rate-limiting step for initiation of alternative NHEJ is the displacement of the Ku complex by PARP1. Therefore, we asked whether PARP1 inhibition could prevent chromosomal translocations in 3 translocation reporter systems. We found that 2 PARP1 inhibitors or repression of PARP1 protein expression strongly repressed chromosomal translocations, implying that PARP1 is essential for this process. Finally, PARP1 inhibition also reduced both ionizing radiation-generated and VP16-generated translocations in 2 cell lines. These data define PARP1 as a critical mediator of chromosomal translocations and raise the possibility that oncogenic translocations occurring after high-dose chemotherapy or radiation could be prevented by treatment with a clinically available PARP1 inhibitor.

UR - http://www.scopus.com/inward/record.url?scp=84880415836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880415836&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-10-460527

DO - 10.1182/blood-2012-10-460527

M3 - Article

C2 - 23568489

AN - SCOPUS:84880415836

VL - 121

SP - 4359

EP - 4365

JO - Blood

JF - Blood

SN - 0006-4971

IS - 21

ER -